IFNA1 and colitis: As noted in the previous section, JAK inhibitors have been shown to alleviate inflammation induced by OSM and IFN in experimental mouse colitis models [143,151], suggesting the potential for JAK inhibitors to be effective in patients with UC exhibiting IL-6, OSM, and IFN-dominant cytokine profiles.